Document:

<PAGE>

                                                                    Exhibit 10.1
                              EMPLOYMENT AGREEMENT

         THIS AGREEMENT (the "Agreement") is made and effective as of March 31,
2003, by and between Bioenvision, Inc, a Delaware Corporation (the "Company"),
and David P. Luci, C.P.A., J.D. (the "Executive").

         WHEREAS, the Company desires to continue to retain the Executive in its
employ as the Director of Finance, General Counsel and Corporate Secretary of
the Company for the period provided in this Agreement, and the Executive has
agreed to continued employment with the Company in accordance with the
contractual terms and conditions set forth below; and

         WHEREAS, this Agreement is intended to, and shall, set forth the
definitive agreement of the parties.

         NOW, THEREFORE, for and in consideration of these recitals and
premises, and the respective promises, covenants and agreements contained
herein, and intending to be legally bound hereby, the parties hereto agree as
follows:

         Section 1. Employment. The Company hereby employs the Executive, and
the Executive hereby accepts such employment with the Company, for the term of
employment set forth in Section 2 hereof, all upon the terms and conditions
hereafter set forth.

         Section 2. Term. Employment shall be for a term commencing on March 31,
2003 and, subject to prior termination under Section 8, Section 9, Section 10,
Section 12 or Section 13 hereof expiring on the one-year anniversary of such
date (March 31, 2004). Notwithstanding the previous sentence, the term of this
Agreement automatically shall be extended for additional one-year terms upon the
terms and conditions set forth herein, unless either party to this Agreement
gives the other party written notice (delivered in accordance with Section 21
hereof and at least 90 days prior to March 31, 2004 or such later termination
date or dates as may be applicable to any extended term) of such party's
intention not to further extend the term of this Agreement. For purposes of this
Agreement, any reference to the "term" of this Agreement shall include the
original term and any extension thereof.

         Section 3. Duties of the Executive. The Executive shall serve as the
Director of Finance, General Counsel and Corporate Secretary of the Company. The
Executive shall perform such executive duties as a Director of Finance, General
Counsel and Corporate Secretary would normally perform or as otherwise specified
in the By-Laws of the Company as in effect on the date of this Agreement, and
shall perform in addition thereto, such other reasonable duties as the Board of
Directors of the Company (together with any applicable sub-committee or
sub-committees thereof, the "Board") may request consistent with Executive's
position and title. Except as may otherwise be approved in advance by the Board
and except during vacation periods and periods of absence due to sickness,
personal injury or other disability, the Executive shall devote all of his
working time and his best efforts to the performance of his duties hereunder.
Notwithstanding the foregoing, nothing contained herein shall preclude the
Executive from (a) serving on the boards of directors of other companies or
organizations with the approval of the Board (not to be unreasonably withheld)
or serving on the boards of directors of not-for-profit companies or
organizations without the approval of the Board, (b) investing in and managing
passive investments, or (c) pursuing his personal, financial and legal affairs
provided that such activity does not materially interfere with the performance
of the Executive's obligations hereunder.

         Section 4. Compensation.

         (a) For the period commencing on the date of this Agreement, the
Executive's base salary shall be $205,200 (and during the term of this
Agreement, not less than $205,200) on an annualized basis. During the term of
the Agreement, the Executive's salary shall be reviewed at least annually by the
Board to determine whether any further increase is warranted and appropriate.
Except as set forth in this Section 4, such compensation shall be payable at the
times and in the manner consistent with the Company's general policies regarding
compensation of executive employees, but in no event less frequently than twice
each calendar month.

         (b) The Company hereby grants and issues to the Executive, incentive
stock options (subject to stockholder approval of the related option plan,
otherwise such options shall be non-qualified stock options under the Internal
Revenue Code) with terms commensurate with the terms of options previously
issued to the Company's management to purchase 380,000 shares of common stock at
an exercise price equal to $.735 (the average of the high and low bid price of
shares of the Company's common stock on the date hereof (the "Grant Date"));
50,000 of which options shall vest immediately on the date hereof and 110,000 of
which options vest on each of the first, second and third anniversaries of the
date hereof (March 31, 2003), or earlier upon Executive's departure for good
reason (pursuant to one or more of the events

<PAGE>

set forth in Sections 9(i) or 9(ii)), a Change of Control (as defined in Section
9) or termination other than for Cause (as defined in Section 8). In addition to
the foregoing, the Company hereby grants and issues to the Executive, incentive
stock options (subject to stockholder approval of the related option plan,
otherwise such options shall be non-qualified stock options under the Internal
Revenue Code) with terms commensurate with the terms of options previously
issued to the Company's management to purchase 120,000 shares of common stock at
an exercise price equal to $.735 (the average of the high and low bid price of
shares of the Company's common stock on the date hereof), which options shall
vest immediately on the date hereof. If Executive resigns other than for good
reason, Executive shall forfeit all unvested stock options issuable hereunder as
of the effective date of such resignation. If Executive is terminated for Cause,
Executive shall forfeit all vested and unvested stock options issued or issuabe
hereunder as of the effective date of such termination. If Executive is
terminated other than for Cause, all of Executive's vested options shall remain
vested and all unvested options shall immediately vest. If a Change of Control
(as defined under Section 9) occurs which prevents any incentive stock options
of Executive from receiving favorable tax treatment under Section 422 of the
Internal Revenue Code of 1986, Executive shall be held harmless from any loss of
such favorable tax treatment.

         (c) In addition to the base salary provided by Section 4(a) hereof and
the incentive stock options provided in Section 4(b) hereof, the Executive shall
be eligible annually to receive any incentive bonus (the "Bonus") that the Board
may grant to him based on the Company's executive compensation plan then in
effect, based on the Board's assessment of the Executive's individual
performance, which decision shall be made by the Board in its sole discretion.
The Board shall give written notice to the Executive of the grant of any such
Bonus and the amount thereof upon direction of the Board. Such Bonus shall be
payable on the next date on which the Executive is entitled to receive a payment
of his base compensation. The Board may from time to time authorize such
additional compensation to the Executive, in cash, property, options or warrants
as the Board may determine in its sore discretion to be appropriate. Payment of
any bonus, if any, is in the sole and absolute discretion of the Board.

         Section 5. Executive Benefits.

         (a) In addition to the compensation described in Section 4, the Company
shall make available to the Executive and his eligible dependants such benefits
which are comparable to those provided to other executive and management
employees of the Company, including without limitation, any medical, group
hospitalization, health, dental care or sick leave plan, life or other insurance
or death benefit plan, travel or accident insurance or other present or future
group employee benefit plan or program of the Company for which key executives
are or shall become eligible.

         (b) The Executive shall be entitled to 4 weeks paid vacation per year,
which shall be pro-rated for partial years. The Executive may carry over from
year to year up to 1 month of unused vacation time. Notwithstanding anything
herein to the contrary, the Executive may not take more than two (2) weeks
vacation during any twelve (12) week period without the prior written permission
of the Board, which shall not be unreasonably withheld. Upon a Change of Control
(as defined in Section 9), Executive promptly shall receive a one-time cash
payment for accrued vacation time at his then-current base salary for up to 1
month of unused vacation time.

         Section 6. Expenses. The Company shall also pay or reimburse the
Executive for all reasonable and necessary expenses incurred by the Executive in
connection with his duties on behalf of the company in accordance with the
general policies of the Company and his employment by the Company pursuant to
this Agreement.

         Section 7. Place of Performance. In connection with his employment by
the Company, unless otherwise agreed by the Executive, the Executive shall be
based at the principal executive offices of the Company in New York City, except
for travel reasonably required for Company business (the "Place of
Performance").

         Section 8. Termination. (a) The Company may terminate Executive's
employment hereunder for "Cause" which shall mean:

         (1) The Executive is indicted for any crime involving moral turpitude
         or punishment by imprisonment;

         (2) Executive's commission of an act of fraud;

         (3) Executive's continuing repeated willful failure or refusal to
         perform his duties as required by this Agreement, provided, that
         termination of Executive's employment pursuant to this subparagraph (c)
         shall not constitute valid termination for Cause unless Executive shall
         have first

<PAGE>

         received written notice from the Board stating with reasonable
         specificity the nature of such failure or refusal and affording
         Executive at least fifteen (15) days to correct the act or omission
         complained of;

         (4) Gross negligence, insubordination, or material violation by
         Executive of any duty of loyalty to the Company or any other material
         misconduct on the part of Executive; or

         (5) A material breach of this Agreement by the Executive.

(b) In addition, the Company may terminate Executive's employment hereunder
without "Cause" (as defined in Section 8(a) above).

         Section 9. Resignation. (a) In the event that during the term of this
Agreement:

         (i) the Company shall (A) fail to continue the Executive as Director of
Finance, General Counsel and Corporate Secretary of the Company; (B) reduce the
Executive's base salary below the minimum amount specified in Section 4(a)
without the Executive's prior written consent; (C) materially violate any
material term of this Agreement (each, a "Permitted Resignation"); or

         (ii) there shall occur a "Change of Control," which shall mean the
occurrence during the term of this Agreement of any of the following events:

(A) the Company is merged, consolidated or reorganized into or with another
corporation or other legal persona, and as a result of such merger,
consolidation or reorganization less than fifty percent (50%) of the combined
voting power of the then outstanding securities entitled to vote generally in
the election of directors ("Voting Stock") of such corporation or person
immediately after such transaction are held in the aggregate by the holders of
Voting Stock of the Company immediately prior to such transaction, or

(B) The Company sells or otherwise transfers all or substantially all of its
assets to another corporation or other legal person, and as a result of such
sale or transfer less than fifty percent (50%) of the combined voting power of
the then outstanding Voting Stock of such corporation or person immediately
after such sale or transfer is held in the aggregate by the holders of Voting
Stock of the Company immediately prior to such sale or transfer, or

(C) Any change in the constitution of the Board of Directors of the Company in
conjunction with a transaction contemplated by Sections 9(ii)(A) or 9(ii)(B)
above;

then, in each case outlined above in this Section 9, the Executive, at his sole
option, may give notice to the Company at any time within ten (10) days after
the occurrence of any such event of his election to resign and terminate this
Agreement effective immediately upon receipt of such notice (delivered in
accordance with Section 21 hereof), or effective upon such other date (not later
than ten (10) days following such notice) that the Executive may designate in
such notice (the "Effective Date") and Executive shall receive the payments and
other compensation provided in Section 4(b) and Section 11.

         In addition to the foregoing, Executive shall have the right to resign
other than such resignation as would constitute a Permitted Resignation or other
than upon a Change of Control.

         Section 10. Death. The term of this Agreement shall terminate on the
death of Executive.

         Section 11. Termination Payment. If the Executive's employment
hereunder is terminated by the Executive by Permitted Resignation, upon a Change
of Control or by the Company other than for Cause, prior to the end of the term
of this Agreement then the Company shall be obligated to pay to the Executive
certain termination payments and make available certain benefits, as follows:

                  (a) Termination Payment. The Company shall pay to the
         Executive a lump sum in cash, payable within ten (10) business days
         after the effective date of such event, equal to 1.50 multiplied by the
         sum of Executive's base salary plus the average of his last two annual
         bonuses (or last one annual bonus, if only one annual bonus has been
         paid to date at the time of such applicable event), in each case,
         pursuant to Section 4.

                  (b) Options. Notwithstanding any provision to the contrary in
         any option agreement or other agreement or in any plan, except for a
         termination for Cause pursuant to Section 8 or a resignation by
         Executive under
<PAGE>
         Section 9 which does not constitute a Permitted Resignation or does not
         occur upon a Change of Control, all of the Executive's outstanding
         stock options shall immediately vest and become exercisable and the
         Executive shall have the full term of the option to exercise any of the
         Executive's stock options.

         Section 12. No other Termination Compensation. Except as specifically
provided above, upon termination of this Agreement for any reason the Executive
shall not be entitled to any severance pay or to any other compensation or
payments (by way of salary, damages or otherwise) of any nature relating to this
Agreement or otherwise relating to or arising out of his employment by the
Company.

         Section 13. Mitigation Obligation. The Executive shall mitigate damages
by seeking other employment or otherwise; provided, however, that the Executive
is under no obligation to mitigate any amount provided for by insurance policies
under this Agreement.

         Section 14. Forum Selection. Any disputes related to the subject matter
hereof shall be litigated in New York courts located within the Southern
District of New York in Manhattan.

         Section 15. Indemnification. To the maximum extent permitted under the
corporate Laws of the State of Delaware, By-Laws and Certificate of
Incorporation of the Company as in effect from time to time:

         (a) the Executive shall be indemnified and held harmless by the
Company, as provided under such corporate laws or such By-Laws, as applicable,
for any and all actions taken or matters undertaken, directly or indirectly, in
the performance of his duties and responsibilities under this Agreement or
otherwise on behalf of the Company, and

         (b) without limiting clause (a), the Company shall indemnify and hold
harmless the Executive from and against (i) any claim, loss, liability,
obligation, damage, cost, expense, action, suit, proceeding or cause of action
(collectively, "Claims".) arising from or out of or relating to the Executive's
performance as an officer, director, employee or agent of the Company or any of
its affiliates or in any other capacity, including, without limitation, any
fiduciary capacity, in which the Executive serves at the request of the Company,
and (ii) any cost or expense (including, without limitation, fees and
disbursements of counsel) (collectively, "Expenses") incurred by the Executive
in connection with the defense or investigation thereof. If any Claim is
asserted or other matter arises with respect to which the Executive believes in
good faith the Executive is entitled to indemnification as contemplated hereby,
the Company shall pay the Expenses incurred by the Executive in connection with
the defense or investigation of such Claim or matter (or cause such Expenses to
be paid) on a monthly basis, provided that the Executive shall reimburse the
Company for such amounts, plus simple interest thereon at the then current prime
rate as reported in the Wall Street Journal as in effect from time to time,
compounded annually, if the Executive shall be found, as finally judicially
determined by a court of competent jurisdiction not to have been entitled to
Indemnification hereunder. Notwithstanding the foregoing, the Company's
obligation to indemnify Executive hereunder shall be subject to (i) timely
notification by Executive hereunder of any claims that are subject to
indemnification under this Section 15 (and any failure of Executive to so notify
the Company which shall cause the Company to compromise any defense to such
claim will cause the Company not to be obligated to indemnify Executive
hereunder) and (ii) the Company will have the right to undertake the defense of
and compromise, settle or otherwise dispose of any claim for which it may be
subject to indemnify Executive hereunder.

         Section 16. Agreement. This Agreement supersedes any and all other
agreements, either oral or written, between the parties hereto with respect to
the subject matter hereof, and contains all of the covenants and agreements
between the parties with respect to such subject matter, and Executive has
received legal counsel regarding the entirety of the Agreement.

         Section 17. Withholding of Taxes. The Company may withhold from any
amounts payable under this Agreement all foreign, federal, state, city or other
taxes as the Company is required to withhold pursuant to any law or government
regulation or ruling.

         Section 18. Successors and Binding Agreement.

         (a) The Company will reasonably require any successor (whether direct
or indirect, by purchase, merger, consolidation, reorganization or otherwise) to
all or substantially all of the business or assets of the Company by agreement
in form and substance satisfactory to the Executive acting reasonably, expressly
to assume and agree to perform this Agreement in the same manner and to the same
extent the Company would be required to perform if no such succession had taken
place. This Agreement will he binding upon and inure to the benefit of the
Company and any successor
<PAGE>

to the Company, including, without limitation any persons acquiring directly or
indirectly all or substantially all of the business or assets of the Company
whether by purchase, merger, consolidation, reorganization or otherwise (and
such Successor shall thereafter be deemed the "Company" for the purposes of this
Agreement).

         (b) This Agreement will inure to the benefit of and be enforceable by
the Executive's personal or legal representatives, executors, administrators,
successors, heirs, distributes and legatees.

         (c) The rights of the Company under this Agreement may without the
consent of Executive, be assigned by the Company in its sole and unfettered
discretion (i) to any person, firm, corporation1 or other business entity which
at any time, whether by purchase, merger, or otherwise, directly or indirectly,
acquires all or substantially all of the assets or business of the Company, or
(ii) to any subsidiary or affiliate of the Company (the "Company Group"), or any
transferee, whether by purchase, merger or otherwise, which directly or
indirectly acquires all or substantially all of the assets of the Company or any
other member of the Company Group.

         Section 19. Notices. For all purposes of this Agreement, all
communications, including, without limitation, notices, consents, request or
approvals, required or permitted to be given hereunder will be in writing and
will be deemed to have been duly given when hand delivered or dispatched by
electronic facsimile transmission (with receipt thereof confirmed), or five
business days after having been mailed by United States registered or certified
mail, return receipt requested, postage prepaid, or three business days after
having been sent by a nationally recognized overnight courier service such as
Federal Express, UPS, or Purolator, addressed to the Company (to the attention
of the Secretary of the Company) at its principal executive offices and to the
Executive at his principal residence, or to such other address as any party may
have furnished to the other in writing and in accordance herewith, except that
notices of changes of address shall be effective only upon receipt.

         Section 20. Governing Law. The validity, interpretation, construction
and performance of this Agreement will be governed by and construed in
accordance with the substantive laws of the State of New York, without giving
effect to the principles of conflict of laws of such State.

         Section 21. Severability and Reformation. If any provision of this
Agreement is held to be illegal, invalid or unenforceable under any present or
future law, and if the rights or obligations of the parties under this Agreement
would not be materially and adversely affected thereby, such provision shall be
fully separable, and this Agreement shall be construed and enforced as if such
illegal, invalid or unenforceable provision had never comprised a part thereof,
the remaining provisions of this Agreement shall remain in full force and effect
and shall not be affected by the illegal, invalid or unenforceable provision or
by its severance therefrom, and, in lieu of such illegal, invalid or
unenforceable provision, there shall be added automatically as a part of this
Agreement a legal, valid and enforceable provision as similar in terms to such
illegal, invalid or unenforceable provision as may be possible, and the parties
hereto request the court or any arbitrator to whom disputes relating to this
Agreement are submitted to reform the otherwise illegal, invalid or
unenforceable provision in accordance with this Section 21.

         Section 22. Survival of Provisions. Notwithstanding any other provision
of this Agreement, the parties respective rights and obligations under Sections
4, 5, 11, 12, 13, 14, 15, 16, 17 and 19 hereof, and under any other Sections
that provide a party with rights (including without limitation, rights to
receive payments) that have not been fully satisfied as of such termination or
expiration, will survive any termination or expiration of this Agreement or the
termination of the Executive's employment for any reason whatsoever.

         Section 23. Miscellaneous. No provision of this Agreement may be
modified, waived or discharged unless such waiver, modification or discharge is
agreed to in writing signed by the Executive and the Company. No waiver by
either party hereto at any time of any breach by the other patty hereto or
compliance with any condition or provision of this Agreement to be performed by
such other party will be deemed a waiver of similar or dissimilar provisions or
conditions at the same or at any prior or subsequent time. Unless otherwise
noted, references to "Sections" are to sections of this Agreement. The captions
used in this Agreement are designed for convenient reference only and are not to
be used for the purpose of interpreting any provision of this Agreement.

         Section 24. Counterparts. This Agreement may be executed in one or more
counterparts, each of which shall be deemed to be an original but all of which
together will constitute one and the same Agreement. The delivery by facsimile
of an executed counterpart of this Agreement shal1 be deemed to be an original
and shall have the full force and effect of an original copy.

         Section 25. Confidentiality.
<PAGE>

         (a) As used herein, the term "Confidential Information" with respect to
any person means all trade secrets and confidential information and know-how of
such person.

         (b) Executive acknowledges that in the course of his employment by the
Company he will acquire Confidential Information of the Company and that such
information constitutes a valuable asset of the Company. Executive shall not,
without the prior written consent of the Company, while employed by the Company
or any time thereafter, use or disclose or enable anyone else to use or disclose
any Confidential Information of the Company (whether or not developed by
Executive), except in the normal course of performing his duties for the
Company.

         (c) In the event that Executive shall at any time receive any
Confidential Information of any third party in connection with his employment by
the Company, he shall maintain such Confidential Information in confidence in
accordance with the Company's obligations to such third party.

         (d) While employed by the Company, Executive shall not use, or disclose
to other employees of the Company, any Confidential Information of his former
employers, former business associates or any other third parties, unless (i)
written permission has been given by such third parties to Executive permitting
Executive to use and/or disclose such information and (ii) the Company approves
in writing of such use and /or disclosure.

     Return of Materials. Upon termination of Executive's employment with the
     Company for any reason (or prior thereto if requested by the Company),
     Executive shall promptly deliver to the Company all documents and other
     materials in his possession, custody or control (whether prepared by
     Executive or others) that relate in any manner to the past, present or
     anticipated business and affairs of the Company, including, without
     limitation, any such documents and materials that contain or constitute
     Confidential Information.

         Section 27. Disclosure of Works and Inventions/Assignment of Patents.
Executive shall promptly disclose to the Company or its nominee any and all
works, inventions, discoveries and improvements that are authored, conceived or
made by Executive while employed by the Company and that relate to the business
or activities of the Company, and Executive hereby assigns and agrees to assign
all of his interest therein to the Company or its nominee. Whenever requested to
do so by the Company, Executive shall execute any and all applications,
assignments or other instruments which the Company shall deem necessary to apply
for and obtain Letters Patent or Copyrights of the United States or any foreign
country or to otherwise protect the Company's interest therein with respect to
such Letters of Patent or Copyrights which relate to the business or activities
of the Company. Such obligations shall continue after Executive's employment
with the Company terminates with respect to works, inventions, discoveries, and
improvements authored, conceived or made by Executive during the period of his
employment by the company, and shall be binding upon Executive's assigns,
executors, administrators and other legal representatives.

         Section 28. Work Made for Hire. Executive acknowledges that his duties
at the Company may include the preparation of materials, including written or
graphic materials, and agrees that any such materials conceived or written by
him shall be done as "work made for hire" as defined and used in the copyright
Act of 1976, 17 U.S.C. 1 et seq. In the event of publication of such materials,
Executive understands that since work is a "work made for hire" the Company will
solely retain and own all rights in such materials, including right of
copyright.

         Section 29. Non-Solicitation and Non-Competition. Executive shall not,
while employed by the Company and during the six month period following the date
on which Executive's employment with the Company terminates for any reason (the
"Specified Period"), directly or indirectly.

                  (i) solicit or induce, or attempt to solicit or induce, any
         employee of the Company to leave the employ of the Company;

                  (ii) employ, or solicit for employment, on his behalf or on
         behalf of any other person (other than the Company), any person that is
         or was at any time an employee of the Company (excluding clerical
         employees); (provided, however, that the foregoing restriction shall
         cease to apply to a former employee of the Company months after he
         ceases to be employed by the Company); or

                  (iii) take any other action detrimental to the relationship of
         the Company with its employees, customers or suppliers.

In addition to the foregoing, while employed by the Company, Executive shall not
(A) solicit the trade of, or trade with, any customer or prospective customer of
the Company (except for the benefit of the Company) or (B) engage in

<PAGE>

any business in the Specified Areas that is competitive with any aspect of the
business that is being conducted (or planned) by the Company.

         Section 30. Other Restrictions on Competition. During the Specified
Period, Executive shall not, whether alone or in association with any other
person, directly or indirectly have any interest or association (including,
without limitation, as a shareholder partner, director, officer, employee,
consultant, sales representative, supplier, distributor, agent or lender) in or
with any person engaged in a business in the Specified Areas that is in
competition with the Company, provided, however, that the foregoing shall not
prohibit Executive from owning securities of any publicity traded company that
is engaged in any such business as long as Executive does not own at any time 5%
or more of any class of the equity securities of such company. For purposes of
the foregoing, the "Specified Areas" means (specify geographic area in which the
Company conducts business).

         Section 31. Equitable Relief. Executive acknowledges that any remedy at
law for any breach of any of the covenants contained in Section 25, 26, 27, 28,
29, 30 hereof may be inadequate. Accordingly, the Company shall be entitled
(without the necessity of showing any actual damage or posting a bond or
furnishing other security) to specific performance or any other mode of
injunctive and/or other equitable relief to enforce its rights under Sections or
any other relief a court might award, such rights to be cumulative with and not
exclusive of any other remedy.

IN WITNESS WHEREOF, the parties hereof have executed this Agreement as of the
day and year first-above written.

                              /s/ David P. Luci
                              -----------------------------
                              David P. Luci

                              BIOENVISION, INC.

                              By:  /s/ Christopher B. Wood
                                   -----------------------
                                   Name:  Christopher B. Wood
                                   Title:  Chairman and Chief Executive Officer<PAGE>

                                                                    Exhibit 10.2

                           GENERAL SERVICES AGREEMENT

This General Services Agreement (the "Agreement") is made and effective as of
March 25, 2003 ("Effective Date"), by and between RRD International, LLC, a
Delaware limited liability company with principal executive offices located at
11 North Washington Street, Suite 310, Rockville, MD 20850 (hereinafter "RRD"),
and Bioenvision, Inc., a Delaware corporation with principal executive offices
located at 509 Madison Avenue, Suite 404, New York, New York 10022 (hereinafter
"Bioenvision"). When executed by both parties hereto, this Agreement will set
forth the terms and conditions under which RRD agrees to provide certain
services to Bioenvision as set forth herein.

                                    Recitals:

WHEREAS, Bioenvision is in the business of developing, manufacturing and/or
distributing pharmaceutical products, biotechnology products and/or medical
devices;

WHEREAS, RRD is engaged in the business of conducting product evaluation and
development on behalf of entities engaged in the development, manufacture,
distribution and/or sale of pharmaceutical products, biotechnology products
and/or medical devices; and

     WHEREAS, Bioenvision and RRD desire to enter into this Agreement, pursuant
     to which RRD will perform the services set forth in this Agreement for
     Bioenvision in connection with the development, manufacture and
     distribution of Bioenvision's clofarabine, trilostane and OLIGON(TM)
     technologies, in each case, as more fully set forth in this Agreement (the
     "Project").

                                   Agreement:

1.0      Services to be Provided. The services to be performed hereunder shall
         be specified in the Scope of Work attached hereto as Addendum 1 (the
         "Scope of Work"), as well as the Project Time line, attached hereto as
         Addendum 2 (the "Project Time Line" and collectively with the Scope of
         Work, the Project Assumptions and the Project Services Checklist, the
         "Services"). RRD and Bioenvision, where appropriate, shall cooperate in
         the completion of a Transfer of Obligations Form in conjunction with
         this Agreement. Any responsibilities not specifically transferred in
         the Transfer of Obligations Form shall remain the regulatory
         responsibility of Bioenvision. The Transfer of Obligations Form will be
         filed with the Food and Drug Administration ("FDA") by Bioenvision,
         where appropriate, or as required by law or regulation, and will be
         attached hereto as Addendum 5 (the "Transfer of Regulatory
         Obligations").

2.0      Payment of Fees and Expenses. Bioenvision will pay RRD for reasonable
         and accountable fees, expenses and pass-through costs in accordance
         with the budget estimate attached hereto as Addendum 3 (the "Budget")
         and in accordance with the payment terms attached hereto as Addendum 4
         (the "Payment Terms"). Bioenvision agrees that the budget and payment
         will be structured in an effort to maintain cash neutrality for RRD
         (with respect to the payment of professional fees, pass-through costs
         and otherwise). RRD acknowledges that prior to the date hereof
         Bioenvision has provided an upfront cash payment to RRD in the amount
         of sixty thousand dollars ($60,000) ("Initial Deposit"). The Initial
         Deposit will be used by RRD to pay its invoices at the time they are
         presented to Bioenvision commencing with the first invoice delivered to
         Bioenvision. Thereafter, RRD shall invoice Bioenvision bi-monthly and
         Bioenvision shall pay each invoice promptly. Any amounts remaining at
         the end of the Project will be applied to the final invoice and any
         amount remaining will be immediately refunded to Bioenvision. The
         currency to be used for invoice and payment shall be U.S. Dollars.

3.0      Term. This Agreement shall commence on the Effective Date that it is
         executed by both parties and shall continue until the Services are
         completed or until terminated by either party in accordance with
         Section 15.0 below.

4.0      Change Orders. Any change in the details of this Agreement or the
         assumptions upon which the Agreement is based (including, but not
         limited to, changes in an agreed starting date for a project or
         suspension of the project by Bioenvision) may require changes in the
         budget and/or time lines and shall require a written amendment to the
         Agreement (a "Change Order"). Each Change Order shall detail the
         requested changes to the applicable task, responsibility, duty, budget,
         time line or other matter. The Change Order will become effective upon
         the execution
<PAGE>

         of the Change Order by both parties and RRD will be given a reasonable
         period of time within which to implement the changes (not to exceed
         thirty days unless otherwise agreed to between the parties). Both
         parties agree to act in good faith and promptly when considering a
         Change Order requested by the other party. RRD reserves the right to
         postpone effecting material changes in the scope of the Services until
         such time as the parties agree to and execute the corresponding Change
         Order. For any Change Order that affects the scope of the regulatory
         obligations that have been or will be transferred to RRD, RRD and
         Bioenvision promptly shall execute a corresponding amendment to the
         Transfer of Obligations Form. Such amendment shall be executed by RRD
         and Bioenvision and filed by Bioenvision with the FDA, where
         appropriate, or as required by law or regulation.

5.0      Confidentiality. It is understood that during the course of this
         Agreement, RRD and its employees may be exposed to data and information
         that is confidential and proprietary to Bioenvision. All such data and
         information, including, without limitation, all analyses, compilations,
         studies, notes, summaries and any and all other records prepared by the
         receiving party that contain or otherwise reflect or are generated by
         such data and information (hereinafter "Bioenvision Confidential
         Information"), written or verbal, tangible or intangible, made
         available, disclosed or otherwise made known by any means to RRD and
         its employees as a result of Services under this Agreement shall be
         considered proprietary and confidential, shall be maintained in strict
         confidence and shall be considered the sole and exclusive property of
         Bioenvision. All information regarding RRD's pricing and RRD's Property
         (as defined in Section 6.0 below), disclosed by RRD to Bioenvision in
         connection with this Agreement is proprietary, confidential information
         belonging to RRD (hereinafter "RRD Confidential Information," and
         together with the Bioenvision Confidential Information, the
         "Confidential Information").

         The Confidential Information shall be used by the receiving party and
         its employees only for purposes of performing the receiving party's
         obligations hereunder. Each party agrees that it will not reveal,
         publish or otherwise disclose the Confidential Information of the other
         party to any third party without the prior written consent of the
         disclosing party. Each party agrees that it will not disclose the terms
         of this Agreement to any third party without the written consent of the
         other party, which shall not unreasonably be withheld. These
         obligations of confidentiality and nondisclosure shall remain in effect
         for a period of ten (10) years after the termination of this Agreement.

         The foregoing obligations shall not apply to Confidential Information
         to the extent that it: (a) is or becomes generally available to the
         public other than as a result of a disclosure by the receiving party;
         (b) becomes available to the receiving party on a non-confidential
         basis from a source that is not prohibited from disclosing such
         information; (c) was developed independently of any disclosure by the
         disclosing party or was known to the receiving party prior to its
         receipt from the disclosing party, as shown by contemporaneous written
         evidence; or (d) is required by law or regulation to be disclosed in
         the reasonable discretion of the disclosing party.

         The parties hereto acknowledge that money damages would be both
         incalculable and an insufficient remedy for any breach of the
         confidentiality restrictions set forth in this Section 5.0, and that
         any such breach would cause the other party irreparable harm.
         Accordingly, the parties hereto agree that in the event of any breach
         or threatened breach hereof by Bioenvision or RRD or by their
         respective representatives, the other party to this Agreement shall be
         entitled, in addition to any other remedy available at law, to
         equitable relief, including, without limitation, injunctive relief
         and/or specific performance without the posting of any bond or other
         security.

6.0      Ownership and Inventions. All data and information, including, without
         limitation, all inventions and/or related patents or other intellectual
         property of any kind or nature, and all improvements thereon and/or
         modifications thereof, in each case, generated or derived by RRD as the
         result of services performed by RRD under this Agreement shall be and
         remain the sole and exclusive property of Bioenvision. Any inventions
         that may evolve from the data and information described above or as the
         result of services performed by RRD under this Agreement shall belong
         exclusively to Bioenvision and RRD agrees to assign any and all of its
         rights in all such inventions and/or related patents or other
         intellectual property of any kind or nature, in each case, to
         Bioenvision. Notwithstanding the foregoing, Bioenvision acknowledges
         that RRD possesses certain inventions, processes, know-how, trade
         secrets, improvements, other intellectual properties and other assets,
         including, but not limited to, analytical methods, procedures and
         techniques, procedure manuals, personnel data, financial information,
         computer technical expertise and software, that have been independently
         developed by RRD and that relate to primarily and directly to its
         business or operations (collectively "RRD's Property"). Bioenvision and
         RRD agree that any of RRD's Property or improvements thereto that are
         used, improved, modified or developed by RRD under or during the term
         of this Agreement are the sole and exclusive property of RRD.

         At the completion of the Services by RRD, all materials, information
         and all other data owned by Bioenvision or that Bioenvision has a right
         to pursuant to the terms of this Agreement, including, without
         limitation, the Bioenvision Confidential Information, regardless of the
         method of storage or retrieval, shall be delivered promptly
<PAGE>

         (but in no event more than thirty (30) days following such completion
         of Services or termination of the Agreement) to Bioenvision in such
         form as is then currently in the possession of RRD, subject to the
         payment obligations set forth in Section 2.0 herein. RRD, however,
         reserves the right to retain, at its own cost and subject to the
         confidentiality provisions herein, one copy of all materials provided
         to Bioenvision as the result of the Services, which material will be
         used solely to satisfy regulatory requirements or to resolve disputes
         regarding the Services. Nothing in this Agreement shall be construed to
         transfer from Bioenvision to RRD any FDA or regulatory record-keeping
         requirements unless such transfer is specifically provided for in the
         applicable Transfer of Obligations Form.

7.0      Independent Contractor Relationship. For the purposes of this
         Agreement, the parties hereto are independent contractors and nothing
         contained in this Agreement shall be construed to place them in the
         relationship of partners, principal and agent, employer/employee or
         joint venturers. Neither party shall have the power or right to bind or
         obligate the other party, nor shall it hold itself out as having such
         authority.

8.0      Representations; Regulatory Compliance; Inspections. RRD represent and
         warrants and covenants to Bioenvision that RRD complies with and will
         continue to comply in all material respects with all applicable state
         and federal laws and regulations applicable to the conduct of its
         business. In addition, RRD covenants to Bioenvision that its Services
         will be conducted in compliance with all applicable state and federal
         laws, rules and regulations, including, but not limited to, the Federal
         Food, Drug and Cosmetic Act and the regulations promulgated pursuant
         thereto and with the standard of care customary in the contract
         research industry. RRD certifies that it has not been debarred under
         the Generic Drug Enforcement Act or under any similar legislation
         promulgated under the laws of the European Community or any member
         state therein and that it will not knowingly employ any person or
         entity that has been so debarred to perform any Services under this
         Agreement. Bioenvision represents and certifies that it will not
         require RRD to perform any assignments or tasks in a manner that would
         violate any applicable law or regulation. Bioenvision further
         represents that it will cooperate with RRD in taking any actions that
         RRD reasonably believes are necessary to comply with the regulatory
         obligations that have been transferred to RRD.

         Each party acknowledges that the other party may respond independently
         to any regulatory correspondence or inquiry in which such party or its
         affiliates is named. However, each party shall: (a) notify the other
         party promptly of any FDA or other governmental or regulatory
         inspection or inquiry concerning any study or project of Bioenvision in
         which RRD is providing Services, including, but not limited to,
         inspections of investigational sites or laboratories; (b) promptly
         forward to the other party copies of any correspondence from any
         regulatory or governmental agency relating to such a study or project,
         including, but not limited to, Form FD-483 notices and FDA refusal to
         file, rejection or warning letters, even if they do not specifically
         mention the other party; (c) obtain the prior written consent of the
         other party, which consent will not be unreasonably withheld, before
         referring to the other party or any of its affiliates in any regulatory
         correspondence or before responding to such regulatory correspondence;
         and (d) use its best efforts to obtain prior written consent, which
         consent shall not be unreasonably withheld, before responding to any
         such regulatory inquiry. Where reasonably practicable, each party will
         be given the opportunity to have a representative present during a FDA
         or regulatory inspection. However, each party acknowledges that it may
         not direct the manner in which the other party fulfills its obligations
         to permit inspection by governmental entities.

         Each party agrees that during an inspection by the FDA or other
         regulatory authority concerning any study or project of Bioenvision in
         which RRD is providing Services, it will not disclose information and
         materials that are not required to be disclosed to such agency without
         the prior written consent of the other party, which consent shall not
         be unreasonably withheld. Such information and materials includes, but
         are not limited to, the following: (a) financial data and pricing data
         (including, but not limited to, the budget and payment schedule); (b)
         sales data (other than shipment data); (c) personnel data (other than
         data as to qualification of technical and professional persons
         performing functions subject to regulatory requirements); and (d)
         Confidential Information.

         During the term of this Agreement, RRD will permit Bioenvision's
         representatives to conduct routine administrative audits on an annual
         basis, which audits shall last no more than two (2) days, to examine or
         audit the work performed hereunder at the facilities at which the work
         is conducted upon reasonable advance notice during regular business
         hours to confirm that the project assignment is being conducted
         adequately in accordance with the agreed upon responsibilities and
         procedures and that the facilities are adequate.

9.0      Relationship with Investigators. If this Agreement obligates RRD to
         contract with investigators or investigative sites (collectively,
         "Investigators"), then any such contract shall be on a form mutually
         acceptable to RRD and Bioenvision. If an Investigator requests any
         material changes to such form, RRD shall submit the proposed change to
         Bioenvision and Bioenvision shall promptly review, comment on and/or
         approve such proposed
<PAGE>

         changes. If Bioenvision approves a form Investigator Agreement, or any
         changes to the form, that differ from the terms of this Agreement
         (including, but not limited to, allowing an Investigator to publish
         results or data that RRD is prohibited from revealing), then RRD shall
         have no liability for any such approved provisions or changes. The
         parties acknowledge and agree that Investigators shall not be
         considered the employees, agents or subcontractors of RRD or
         Bioenvision, and that Investigators shall exercise their own
         independent medical judgment. RRD's responsibilities with respect to
         Investigators shall be limited to those responsibilities specifically
         set forth in this Agreement.

         If RRD will be paying Investigators on behalf of Bioenvision, the
         parties will agree to a pre-approved, written schedule of amounts to be
         paid to Investigators. Bioenvision acknowledges and agrees that RRD
         will only pay Investigators from advances or pre-payments received from
         Bioenvision for Investigators' services and that RRD will not make
         payments to Investigators prior to receipt of sufficient funds from
         Bioenvision. Bioenvision acknowledges and agrees that RRD will not be
         responsible for delays in a study or project to the extent that such
         delays are caused by Bioenvision's failure to make adequate pre-payment
         for Investigators' services. Bioenvision further acknowledges and
         agrees that payments for Investigators' services are pass-through
         payments to third parties and are separate from payments for RRD's
         Services. Bioenvision agrees that it will not withhold Investigator
         payments except to the extent that it has reasonable questions about
         the services performed by a particular Investigator.

10.0     Conflict of Agreements; Non-Competition. RRD represents to Bioenvision
         that it is not a party to any agreement that would prevent it from
         fulfilling its obligations under this Agreement and that during the
         term of this Agreement, RRD will not enter into any agreement to
         provide services that would in any way prevent it from providing the
         services contemplated under this Agreement. Bioenvision agrees that it
         will not enter into an agreement with a third party that would alter or
         affect the regulatory obligations delegated to RRD pursuant to this
         Agreement without the written consent of RRD, which consent will not be
         unreasonably withheld; provided, however, that the parties hereto
         acknowledge and agree that any regulatory obligations delegated to RRD
         during the Term of this Agreement may be revised in accordance with
         Section 4.0 hereof..

         RRD represents that it is not a party to any agreement, nor shall RRD
         enter into any agreement during the term of this Agreement, to develop
         products for, or in conjunction with, any person or entity that consist
         of compounds with the same mechanisms of actions (i.e. same molecular
         targets) for the same indications as any of Bioenvision's products.

11.0     Publication. Project results may not be published or referred to, in
         whole or in part, by RRD or its affiliates without the prior express
         written consent of Bioenvision. Neither party will use the other
         party's name in connection with any publication or promotion without
         the other party's prior written consent, except as required by law,
         including, without limitation, the rules and regulations of the FDA or
         the Securities and Exchange Commission.

12.0     Limitation of Liability. In no event shall the collective, aggregate
         liability (including, but not limited to, contract, negligence and tort
         liability, as well as for any special, incidental, indirect or
         consequential damages, including, but not limited to, the loss of
         opportunity, loss of use or loss of revenue or profit in connection
         with or arising out of this Agreement or the Services performed
         hereunder) of RRD and its respective directors, officers, employees and
         agents under this Agreement exceed the greater of (a) two times the
         aggregate fees earned by RRD pursuant to this Agreement from and after
         the date hereof, or (b) three million U.S. dollars ($3,000,000).

13.0     Indemnification. Bioenvision shall indemnify, defend and hold harmless
         RRD and its directors, officers, employees and agents (each, a "RRD
         Indemnified Party"), from and against any and all losses, damages,
         liabilities, reasonable attorney fees, court costs and expenses
         (collectively "Losses") resulting from or arising out of any breach of
         this Agreement or any third-party claims, actions, proceedings,
         investigations or litigation relating to, arising from or in connection
         with this Agreement or the Services contemplated herein (including,
         without limitation, any Losses arising from or in connection with any
         study, test, device, product or potential product to which this
         Agreement relates), except to the extent such Losses are determined to
         have resulted from the gross negligence, reckless or willful misconduct
         or intentional misconduct of the RRD Indemnified Party seeking
         indemnity hereunder.

         RRD shall indemnify, defend and hold harmless Bioenvision and its
         affiliates, and its and their directors, officers, employees and agents
         (each, a "Bioenvision Indemnified Party"), from and against any and all
         losses, damages, liabilities, reasonable attorney fees, court costs,
         and expenses (collectively "Bioenvision Losses") resulting or arising
         from any breach of this Agreement or any third-party claims, actions,
         proceedings, investigations or litigation relating to or arising from
         or in connection with this Agreement or the Services contemplated
         herein (including, without limitation, any Bioenvision Losses arising
         from or in connection with any study, test, device,
<PAGE>

         product or potential product to which this Agreement relates), to the
         extent such Bioenvision Losses are determined to have resulted from the
         gross negligence, reckless or willful misconduct or intentional
         misconduct of RRD.

14.0     Indemnification Procedure. The party seeking indemnification hereunder
         shall give the indemnifying party prompt notice of any such claim or
         lawsuit (including a copy thereof) served upon it and shall fully
         cooperate with the indemnifying party and its legal representatives in
         the investigation of any matter that is the subject of indemnification.
         The party seeking indemnification shall not unreasonably withhold its
         approval of the settlement of any claim, liability, or action covered
         by this Indemnification provision.

15.0     Termination. This Agreement may be terminated without cause by
         Bioenvision or by RRD, in each case, in such party's sole and absolute
         discretion, at any time during the term of the Agreement on thirty (30)
         days' prior written notice to RRD or Bioenvision, as appropriate.
         Either party may terminate this Agreement for material breach upon
         thirty (30) days' prior written notice specifying the nature of the
         breach, if such breach has not been cured within the succeeding 30-day
         period as determined by the reasonable discretion of the non-breaching
         party. In the event that RRD or Bioenvision, as the case may be,
         determines that RRD's continued performance of the Services
         contemplated by this Agreement would constitute a potential or actual
         violation of regulatory or scientific standards of integrity, either
         such party may terminate this Agreement by giving written notice to the
         other stating the effective date (which may be less than thirty (30)
         days from the notice date) of such termination.

         In the event this Agreement is terminated, Bioenvision shall pay RRD
         for all Services performed in accordance with this Agreement and
         reimburse RRD for all costs and expenses incurred in performing those
         Services, in each case, through the effective date of such termination.
         Upon receipt of a termination notice, RRD shall cease performing any
         work not necessary for the orderly close out of the Services or for the
         fulfillment of regulatory requirements. Bioenvision shall pay for all
         actual costs, including time spent by RRD's personnel (which shall be
         billed at RRD's standard rates included in RRD's business proposal to
         Bioenvision, as may be amended or supplemented from time to time),
         incurred to complete activities associated with the termination and
         close out of the project or Services, including the fulfillment of any
         regulatory requirements. If the termination is not due to a breach by
         or other failure of RRD, Bioenvision also shall pay the standard rates
         of any RRD personnel exclusively assigned to the terminated project or
         Services (provided that such personnel's time is not already being
         billed for close-down services) from the date of the notice of
         termination until the effective date of termination, or until thirty
         (30) days from receipt of the notice, whichever is first to occur. RRD
         shall make all reasonable efforts in good faith to promptly re-assign
         such personnel.

         Upon the termination of this Agreement, RRD promptly shall deliver to
         Bioenvision all data and materials provided by Bioenvision to RRD for
         the conduct of Services under the impacted Project. All statistical
         data, all statistical reports, all data entries and any other
         documentation produced as the result of Services performed by RRD under
         the impacted Project shall be delivered to Bioenvision promptly upon
         payment to RRD for all Services completed in accordance with this
         Agreement (but in no event later than three (3) days following such
         payment to RRD unless otherwise agreed to between the parties). RRD
         shall cooperate in good faith to ensure the orderly transition of all
         such data and materials with respect to the impacted Project(s) to
         Bioenvision or its designee.

16.0     Cooperation; Delays; Disclosure of Hazards. Bioenvision shall forward
         to RRD in a timely manner all data and information in Bioenvision's
         possession or control necessary for RRD to conduct the Services under
         this Agreement. RRD shall not be liable to Bioenvision nor be deemed to
         have breached this Agreement for errors, delays or other consequences
         arising primarily and directly from Bioenvision's failure to provide
         documents, materials or information or to otherwise cooperate with RRD
         in order for RRD to timely and properly perform its obligations, except
         to the extent that, by any act or omission of RRD, such errors, delays
         or other consequences are caused by or relate to the gross negligence
         or intentional misconduct of RRD. Bioenvision acknowledges that, if it
         materially delays or suspends performance of the Services, then the
         personnel and/or resources originally allocated to the project may be
         re-allocated and RRD will not be responsible for delays due to required
         re-staffing or re-allocation of resources. Bioenvision shall provide
         RRD with all information available to it regarding known or potential
         hazards associated with the use of any substances supplied to RRD by
         Bioenvision and Bioenvision shall not, to its knowledge, fail to comply
         with any current legislation and regulations concerning the shipment of
         substances by the land, sea or air.

17.0     Force Majeure. In the event either party shall be delayed or hindered
         in or prevented from the performance of any act required hereunder by
         reasons of strike, lockouts, labor troubles, inability to procure
         materials or services, failure of power or restrictive government,
         judicial orders or decrees, riots, insurrection, war, Acts of God,
         inclement weather, or other reason or cause beyond that party's
         control, then performance of such act (except for the payment of money
         owed) shall be excused for the period of such delay.
<PAGE>

18.0     Notices and Deliveries. Any notice required or permitted to be given
         hereunder by either party hereunder shall be in writing and shall be
         deemed given on the date received if delivered personally or by a
         reputable overnight delivery service, or three (3) days after the date
         postmarked if sent by registered or certified mail, return receipt
         requested, postage prepaid to the following addresses:

         If to RRD:
                                    Charles W. Finn, Ph.D.
                                    Chief Operating Officer
                                    Chief Development Officer
                                    RRD International, Inc.
                                    11 North Washington Street, Suite 310
                                    Rockville, MD  20850

         With a copy to:            Carol Ann Brideau
                                    RRD International, Inc.
                                    11 North Washington Street, Suite 310
                                    Rockville, MD  20850

     If to Bioenvision:             Bioenvision, Inc.
                                    509 Madison Avenue, Suite 404
                                    New York, New York 10022
                                    Attention:  Chairman and General Counsel

     With a copy to:                Paul, Hastings, Janofsky & Walker LLP
                                    75 East 55th Street
                                    New York, New York 10022
                                    Attention:  Luke P. Iovine, III, Esq.

         If Bioenvision delivers, ships or mails materials or documents to RRD,
         or requests that RRD deliver, ship or mail materials or documents to
         Bioenvision or to third parties, then the expense and risk of loss for
         such deliveries, shipments or mailings shall be borne by Bioenvision.
         RRD disclaims any liability for the actions or omissions of third-party
         delivery services or carriers.

19.0     Insurance. RRD will maintain, for the duration of this Agreement,
         insurance in an amount reasonably adequate to cover its obligations
         hereunder and, upon request, RRD will provide Bioenvision with a
         certificate of insurance showing that such insurance is in place.

20.0     Assignment. Neither party may assign any of its rights or obligations
         under this Agreement to any party without the express, written consent
         of the other party, which consent shall not be unreasonably withheld or
         delayed.

21.0     Choice of Law and Enforceability. This Agreement shall be construed,
         governed, interpreted, and applied in accordance with the laws of the
         State of Delaware, exclusive of its conflicts of laws provisions. The
         failure to enforce any right or provision herein shall not constitute a
         waiver of that right or provision. If any provisions herein are found
         to be unenforceable on the grounds that they are overly broad or in
         conflict with applicable laws, it is the intent of the parties that
         such provisions be replaced, reformed or narrowed so that their
         original business purpose can be accomplished to the extent permitted
         by law and so that the remaining provisions shall not in any way be
         affected or impaired thereby.

22.0     Survival. The rights and obligations of Bioenvision and RRD, which by
         intent or meaning have validity beyond such termination (including, but
         not limited to, the rights with respect to product-related inventions,
         confidentiality, discoveries and improvements, indemnification and
         liability limitations) shall survive the termination of this Agreement.
<PAGE>

23.0     Arbitration. Any controversy or claim arising out of, or relating to,
         this Agreement or the breach thereof shall be settled by arbitration
         administered by the American Arbitration Association ("AAA") under its
         Commercial Arbitration Rules and judgment on the award rendered by the
         arbitrator shall be binding and may be entered in any court having
         jurisdiction thereof. Such arbitration shall be filed and conducted in
         the county and city of New York and shall be conducted in English by
         one arbitrator mutually acceptable to the parties selected in
         accordance with AAA Rules.

<PAGE>

24.0     Entire Agreement and Modification. This Agreement contains the entire
         understandings of the parties with respect to the subject matter
         herein, and supersedes all previous agreements (oral and written),
         negotiations and discussions. Any modifications to the provisions
         herein must be in writing and signed by the parties.

IN WITNESS WHEREOF, this Agreement has been executed by the parties hereto
through their duly authorized officers on the date first-above written.

<TABLE>
<CAPTION>

                      ACKNOWLEDGED, ACCEPTED AND AGREED TO:

RRD INTERNATIONAL, LLC                                        BIOENVISION, INC.
<S>                                                           <C>

By:        /s/ Joseph P. Clancy                               By:      /s/ David P. Luci
   --------------------------------------------------            -------------------------------------------------

Name:      Joseph P. Clancy                                   Name:    David P. Luci
     ------------------------------------------------              -----------------------------------------------

Title:     Chief Executive Officer                            Title:   Director of Finance and General Counsel
      -----------------------------------------------               ----------------------------------------------

FEDERAL ID #  02-0671939                                      FEDERAL ID # 13-4025857
            -----------------------------------------                     ----------------------------------------

</TABLE>

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00052-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00052-of-00352.parquet"}]]